X 4 Pharmaceuticals Inc stock is traded at $3.18, with a volume of 527,190. It is up +3.58% in the last 24 hours and up +14.80% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Previous Close:
$3.07
Open:
$3.04
24h Volume:
527,190
Relative Volume:
0.72
Market Cap:
$324.72M
Revenue:
$9.01M
Net Income/Loss:
-$99.72M
P/E Ratio:
-
EPS:
-$4.54
Net Cash Flow:
-$92.85M
1W Performance:
-5.07%
1M Performance:
+14.80%
6M Performance:
-27.40%
1Y Performance:
-9.27%
1-Day Range:
$2.90$3.21
1-Week Range:
$2.90$3.47
52-Week Range:
$2.43$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
857-529-8300Address
61 NORTH BEACON STREET, BOSTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS